<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39428405</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>20</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>20</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Prognostic model for gastric cancer patients with COVID-19 and network pharmacology study on treatment by lentinan.</ArticleTitle><Pagination><StartPage>24645</StartPage><MedlinePgn>24645</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">24645</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-76783-2</ELocationID><Abstract><AbstractText>Patients with gastric cancer (GC) are more susceptible to coronavirus disease 2019 (COVID-19), which further worsens their already challenging prognosis. However, there are no effective treatment options for these patients. Lentinan is a potent bioactive component with antiviral and antitumor effects. We hypothesized that lentinan might exert powerful pharmacological effects in patients with GC and COVID-19. In this study, a prognostic model of patients with GC/COVID-19 was constructed and used to apply a network pharmacology approach to reveal biological functions, drug targets, and molecular mechanisms of the action of lentinan against GC/COVID-19. Clinical analysis revealed key prognostic genes in patients with GC/COVID-19. The results of network pharmacology analysis suggested that the therapeutic effect of lentinan on GC/COVID-19 mainly involves the modulation of several neutrophil-related biological processes, as well as the nucleotide-binding and oligomerization domain-like receptor and interleukin-17 signaling pathways. In addition, C-X-C motif chemokine ligand 8, vascular endothelial growth factor A, ribonuclease 3, and F2 were identified as key genes of lentinan against GC/COVID-19. Key prognostic genes were identified in patients with GC/COVID-19 through the construction of a prognostic model. Pharmacological functions and signaling pathways of lentinan against GC/COVID-19 were revealed. These included the regulation of neutrophils and NOD-like receptor signaling pathways. The findings provide the first published evidence of the potential value of lentinan as a complementary therapy for GC/COVID-19.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Sitong</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of General Surgery Department, The second hospital of Jilin University, Changchun, 130041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Hao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of General Surgery Department, The second hospital of Jilin University, Changchun, 130041, China. drsunhao@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>37339-90-5</RegistryNumber><NameOfSubstance UI="D007912">Lentinan</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013274" MajorTopicYN="Y">Stomach Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007912" MajorTopicYN="Y">Lentinan</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000091484" MajorTopicYN="Y">Network Pharmacology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Gastric cancer</Keyword><Keyword MajorTopicYN="N">Lentinan</Keyword><Keyword MajorTopicYN="N">Molecular docking</Keyword><Keyword MajorTopicYN="N">Network pharmacology</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>20</Day><Hour>23</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39428405</ArticleId><ArticleId IdType="pmc">PMC11491479</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-76783-2</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-76783-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yu, J., Ouyang, W., Chua, M. L. K. &amp; Xie, C. SARS-CoV-2 transmission in patients with Cancer at a Tertiary Care Hospital in Wuhan, China. JAMA Oncol. 6 (7), 1108–1110 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7097836</ArticleId><ArticleId IdType="pubmed">32211820</ArticleId></ArticleIdList></Reference><Reference><Citation>Thrift, A. P. &amp; El-Serag, H. B. Burden of gastric Cancer. Clin. Gastroenterol. Hepatol. 18 (3), 534–542 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8859863</ArticleId><ArticleId IdType="pubmed">31362118</ArticleId></ArticleIdList></Reference><Reference><Citation>Karimi, P., Islami, F., Anandasabapathy, S., Freedman, N. D. &amp; Kamangar, F. Gastric Cancer: descriptive epidemiology, risk factors, screening, and Prevention. Cancer Epidemiol. Biomarkers Prev. 23 (5), 700–713 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4019373</ArticleId><ArticleId IdType="pubmed">24618998</ArticleId></ArticleIdList></Reference><Reference><Citation>Makeeva, Т. K. &amp; Galkin, A. A. Nutritional status of the gastric cancer patients. Vestnik Saint Petersburg Univ. Med. S1, 105–117 (2008).</Citation></Reference><Reference><Citation>Chihara, G., Maeda, Y., Hamuro, J., Sasaki, T. &amp; Fukuoka, F. Inhibition of mouse sarcoma 180 by polysaccharides from Lentinus edodes (Berk.) Sing. Nature. 222 (5194), 687–688 (1969).</Citation><ArticleIdList><ArticleId IdType="pubmed">5768289</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Y. Y., Li, S., Wang, X. H., Zhang, L. N. &amp; Cheung, P. C. K. Advances in lentinan: isolation, structure, chain conformation and bioactivities. Food Hydrocoll. 25 (2), 196–206 (2011).</Citation></Reference><Reference><Citation>Ren, L., Perera, C. &amp; Hemar, Y. Antitumor activity of mushroom polysaccharides: a review. Food Funct. 3 (11), 1118–1130 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22865023</ArticleId></ArticleIdList></Reference><Reference><Citation>Lull, C., Wichers, H. J. &amp; Savelkoul, H. F. Antiinflammatory and immunomodulating properties of fungal metabolites. Mediators Inflamm. 2005 (2), 63–80 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1160565</ArticleId><ArticleId IdType="pubmed">16030389</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreenivasulu, K., Vijayalakshmi, M. &amp; Sambasivarao, K. R. Regulation studies of telomerase gene in cancer cells by lentinan. Avicenna J. Med. Biotechnol. 2 (4), 181–185 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3558165</ArticleId><ArticleId IdType="pubmed">23408759</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto, T. et al. Suppressive effect of polysaccharides from the edible and medicinal mushrooms, Lentinus edodes and Agaricus Blazei, on the expression of cytochrome P450s in mice. Biosci. Biotechnol. Biochem. 66 (7), 1610–1614 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12224654</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren, G. M., Xu, L. M., Lu, T. Y. &amp; Yin, J. S. Structural characterization and antiviral activity of lentinan from Lentinus edodes mycelia against infectious hematopoietic necrosis virus. Int. J. Biol. Macromol. 115, 1202–1210 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29704603</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkar, S., Koga, J., Whitley, R. J. &amp; Chatterjee, S. Antiviral effect of the extract of culture medium of Lentinus edodes mycelia on the replication of herpes simplex virus type 1. Antiviral Res. 20 (4), 293–303 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8387258</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki, H. et al. Inhibition of the infectivity and cytopathic effect of human immunodeficiency virus by water-soluble lignin in an extract of the culture medium of Lentinus edodes mycelia (LEM). Biochem. Biophys. Res. Commun. 160 (1), 367–373 (1989).</Citation><ArticleIdList><ArticleId IdType="pubmed">2469420</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, X., Wang, Z. Y., Zheng, J. H. &amp; Li, S. TCM network pharmacology: a new trend towards combining computational, experimental and clinical approaches. Chin. J. Nat. Med. 19 (1), 1–11 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33516447</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo, T. T. et al. Network Pharmacology in Research of Chinese Medicine Formula: methodology, application and prospective. Chin. J. Integr. Med. 26 (1), 72–80 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">30941682</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, J. et al. An Integrated TCGA Pan-cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell. 173 (2), 400– (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6066282</ArticleId><ArticleId IdType="pubmed">29625055</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, R. et al. Network Pharmacology and bioinformatics analyses identify intersection genes of niacin and COVID-19 as potential therapeutic targets. Brief. Bioinform. 22 (2), 1279–1290 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7717147</ArticleId><ArticleId IdType="pubmed">33169132</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher, L. D. &amp; Lin, D. Y. Time-dependent covariates in the Cox proportional-hazards regression model. Annu. Rev. Public. Health. 20, 145–157 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10352854</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang, S. et al. HERB: a high-throughput experiment- and reference-guided database of traditional Chinese medicine. Nucleic Acids Res. 49 (D1), D1197–D1206 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7779036</ArticleId><ArticleId IdType="pubmed">33264402</ArticleId></ArticleIdList></Reference><Reference><Citation>Daina, A., Michielin, O. &amp; Zoete, V. Swiss target prediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res. 47 (W1), W357–W364 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6602486</ArticleId><ArticleId IdType="pubmed">31106366</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, X. et al. PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database. Nucleic Acids Res. 45 (W1), W356–W360 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5793840</ArticleId><ArticleId IdType="pubmed">28472422</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa, M. &amp; Goto, S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28 (1), 27–30 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC102409</ArticleId><ArticleId IdType="pubmed">10592173</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 28 (11), 1947–1951 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6798127</ArticleId><ArticleId IdType="pubmed">31441146</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M. &amp; Ishiguro-Watanabe, M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 51 (D1), D587–d592 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9825424</ArticleId><ArticleId IdType="pubmed">36300620</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu, G., Wang, L-G., Han, Y. &amp; He, Q-Y. clusterProfiler: an R Package for comparing Biological themes among Gene clusters. Omics-a J. Integr. Biology. 16 (5), 284–287 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3339379</ArticleId><ArticleId IdType="pubmed">22455463</ArticleId></ArticleIdList></Reference><Reference><Citation>Trott, O. &amp; Olson, A. J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31 (2), 455–461 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3041641</ArticleId><ArticleId IdType="pubmed">19499576</ArticleId></ArticleIdList></Reference><Reference><Citation>Moujaess, E., Kourie, H. R. &amp; Ghosn, M. Cancer patients and research during COVID-19 pandemic: a systematic review of current evidence. Crit. Rev. Oncol. Hematol. 150, 102972 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7174983</ArticleId><ArticleId IdType="pubmed">32344317</ArticleId></ArticleIdList></Reference><Reference><Citation>Ribas, A. et al. Priority COVID-19 vaccination for patients with Cancer while Vaccine Supply is Limited. Cancer Discov. 11 (2), 233–236 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8053003</ArticleId><ArticleId IdType="pubmed">33355178</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai, M. et al. Patients with Cancer Appear more vulnerable to SARS-CoV-2: a Multicenter Study during the COVID-19 outbreak. Cancer Discov. 10 (6), 783–791 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7309152</ArticleId><ArticleId IdType="pubmed">32345594</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomazini, B. M. et al. Effect of dexamethasone on days alive and Ventilator-Free in patients with moderate or severe Acute Respiratory Distress Syndrome and COVID-19: the CoDEX Randomized Clinical Trial. JAMA. 324 (13), 1307–1316 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7489411</ArticleId><ArticleId IdType="pubmed">32876695</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, M., Zhang, Y., Zhang, L. &amp; Tian, Q. Mushroom polysaccharide lentinan for treating different types of cancers: a review of 12 years clinical studies in China. Prog Mol. Biol. Transl Sci. 163, 297–328 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31030752</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, J., Wang, H. Y., Xia, X. M., Li, P. P. &amp; Wang, K. Y. Inhibitory effect of sulfated lentinan and lentinan against tobacco mosaic virus (TMV) in tobacco seedlings. Int. J. Biol. Macromol. 61, 264–269 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23850557</ArticleId></ArticleIdList></Reference><Reference><Citation>Philpott, D. J., Sorbara, M. T., Robertson, S. J., Croitoru, K. &amp; Girardin, S. E. NOD proteins: regulators of inflammation in health and disease. Nat. Rev. Immunol. 14 (1), 9–23 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24336102</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabbah, A. et al. Activation of innate immune antiviral responses by Nod2. Nat. Immunol. 10 (10), 1073–1080 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2752345</ArticleId><ArticleId IdType="pubmed">19701189</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, S. et al. Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation. Science. 347 (6227), aaa2630 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25636800</ArticleId></ArticleIdList></Reference><Reference><Citation>Udden, S. M. N. et al. NOD2 suppresses colorectal tumorigenesis via downregulation of the TLR pathways. Cell. Rep. 19 (13), 2756–2770 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6032983</ArticleId><ArticleId IdType="pubmed">28658623</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida-da-Silva, C. L. C., Savio, L. E. B., Coutinho-Silva, R. &amp; Ojcius, D. M. The role of NOD-like receptors in innate immunity. Front. Immunol. 14, 1122586 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10050748</ArticleId><ArticleId IdType="pubmed">37006312</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeachy, M. J., Cua, D. J. &amp; Gaffen, S. L. The IL-17 family of cytokines in Health and Disease. Immunity. 50 (4), 892–906 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6474359</ArticleId><ArticleId IdType="pubmed">30995505</ArticleId></ArticleIdList></Reference><Reference><Citation>Coffelt, S. B. et al. IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis. Nature. 522 (7556), 345–348 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4475637</ArticleId><ArticleId IdType="pubmed">25822788</ArticleId></ArticleIdList></Reference><Reference><Citation>Buja, L. M. et al. The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities. Cardiovasc. Pathol. 48, 107233 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7204762</ArticleId><ArticleId IdType="pubmed">32434133</ArticleId></ArticleIdList></Reference><Reference><Citation>Cecchini, R. &amp; Cecchini, A. L. SARS-CoV-2 infection pathogenesis is related to oxidative stress as a response to aggression. Med. Hypotheses ;143. (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7357498</ArticleId><ArticleId IdType="pubmed">32721799</ArticleId></ArticleIdList></Reference><Reference><Citation>Laforge, M. et al. Tissue damage from neutrophil-induced oxidative stress in COVID-19. Nat. Rev. Immunol. 20 (9), 515–516 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7388427</ArticleId><ArticleId IdType="pubmed">32728221</ArticleId></ArticleIdList></Reference><Reference><Citation>Aikawa, N. &amp; Kawasaki, Y. Clinical utility of the neutrophil elastase inhibitor sivelestat for the treatment of acute respiratory distress syndrome. Ther. Clin. Risk Manag. 10, 621–629 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4130327</ArticleId><ArticleId IdType="pubmed">25120368</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng, W., Song, Y., Wang, R., He, R. &amp; Wang, T. Neutrophil elastase: from mechanisms to therapeutic potential. J. Pharm. Anal. 13 (4), 355–366 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10173178</ArticleId><ArticleId IdType="pubmed">37181292</ArticleId></ArticleIdList></Reference><Reference><Citation>Szturmowicz, M. &amp; Demkow, U. Neutrophil Extracellular traps (NETs) in severe SARS-CoV-2 Lung Disease. Int. J. Mol. Sci. ;22(16). (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8396177</ArticleId><ArticleId IdType="pubmed">34445556</ArticleId></ArticleIdList></Reference><Reference><Citation>Middleton, E. A. et al. Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood. 136 (10), 1169–1179 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7472714</ArticleId><ArticleId IdType="pubmed">32597954</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavalcante-Silva, L. H. A. et al. Neutrophils and COVID-19: the road so far. Int. Immunopharmacol. 90, 107233 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7703515</ArticleId><ArticleId IdType="pubmed">33290963</ArticleId></ArticleIdList></Reference><Reference><Citation>Masso-Silva, J. A. et al. Increased peripheral blood neutrophil activation phenotypes and Neutrophil Extracellular trap formation in critically ill coronavirus Disease 2019 (COVID-19) patients: a Case Series and Review of the literature. Clin. Infect. Diseases: Official Publication Infect. Dis. Soc. Am. 74 (3), 479–489 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8241438</ArticleId><ArticleId IdType="pubmed">33988226</ArticleId></ArticleIdList></Reference><Reference><Citation>Lungu, C. N. &amp; Mehedinti, M. C. Molecular motifs in vascular morphogenesis: vascular endothelial growth factor A (VEGFA) as the leading promoter of Angiogenesis. Int. J. Mol. Sci. ;24(15). (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10418718</ArticleId><ArticleId IdType="pubmed">37569543</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu, L. et al. Human RNase3 immune modulation by catalytic-dependent and independent modes in a macrophage-cell line infection model. Cell. Mol. Life Sci. 78 (6), 2963–2985 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8004517</ArticleId><ArticleId IdType="pubmed">33226440</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba, T., Levy, J. H., Levi, M. &amp; Thachil, J. Coagulopathy in COVID-19. J. Thromb. Haemost. 18 (9), 2103–2109 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7323352</ArticleId><ArticleId IdType="pubmed">32558075</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>